Entity

Time filter

Source Type

Salerno, Italy

Patent
Biouniversa Srl | Date: 2014-12-16

The present invention concerns the field of diagnostic biological markers. Specifically the invention relates to BAG3 RNA or a fragment thereof for use as biological markers for the diagnosis of a pathological state. Furthermore, the invention involves specific kits and methods, for detecting and/or evaluating the levels of BAG3 RNA or a fragment thereof in a biological sample.


Patent
Biouniversa Srl | Date: 2014-03-04

The present invention relates to the use of BAGS antibodies as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic and/or degenerative nature.


Cichero E.,University of Genoa | Basile A.,University of Salerno | Basile A.,Biouniversa Srl | Turco M.C.,University of Salerno | And 3 more authors.
Medicinal Chemistry Research | Year: 2012

HSC70 has been identified as an important molecular target involved in the ΔF508-CFTR cystic fibrosis. HSC70 associates ΔF508-CFTR to a much greater extent than WT-CFTR and after this step, it recruits other co-chaperones (BAG1, CHIP) and performs the ubiquitination and proteosomal degradation of the protein. Up to now, several X-ray data concerning the HSC70:BAG1 complexes are available. Thus, we performed an "in silico" investigation focused to explore which different amino acid residues are involved in the binding of ATP, the natural substrate, and the co-crystallized ligands at the HSC70/BAG-1 interface. The study allowed us to evaluate sildenafil and KM11060, which proved to be also CFTR correctors, as potential HSC70:BAG1 inhibitors, and also let us derive interesting perspectives for the development of new CFTR correctors. © 2012 Springer Science+Business Media, LLC. Source


Palma G.,Struttura Semplice Dipartimentale Sperimentazione Animale | Palma G.,University of Naples Federico II | De Laurenzi V.,University of Chieti Pescara | De Laurenzi V.,Biouniversa Srl | And 7 more authors.
Biochimica et Biophysica Acta - Reviews on Cancer | Year: 2012

Dendritic cells (DCs) are immunological sentinels of the organism acting as antigen-presenting cells (APC) and are critical for induction of innate and adaptive immunity. Traditionally they are divided in myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs), a rare population of circulating cells that selectively express Toll-like receptors (TLR) 7 and TLR9 and have the capacity to produce large amounts of type I interferons (IFNs) in response to pathogenic agents or danger signals. It has been demonstrated that pDCs can coordinate events during the course of viral infections, allergic and autoimmune diseases and cancer. Through the production of type I IFNs, pDCs initiate protective immunity by activating classical DCs, T cells, natural killer cells and B cells. Upon activation, pDCs also differentiate into mature DCs and may contribute to the contraction of T-cell response. Human pDCs preferentially express immunoglobulin-like transcript 7 (ILT7; LILRA4), which couples with a signaling adapter to activate a prominent immune-receptor tyrosine-based activation motif (ITAM)-mediated signaling pathway. The interaction between ILT7 and bone marrow stromal cell antigen 2 (BST2, CD317) assures an appropriate TLR response by pDCs during viral infections and likely participates in pDCs tumor crosstalk. Moreover these cells seem to play a crucial role in the initiation of the pathological process of autoimmune diseases such as lupus or psoriasis. Despite the fact that their function within a tumor context is still controversial they represent an attractive target for therapeutic manipulation of the immune system to elicit a powerful immune response against tumor antigens in combination with other therapies. © 2012. Source


Rosati A.,Biouniversa Srl | Rosati A.,University of Salerno | Basile A.,Biouniversa Srl | Basile A.,University of Salerno | And 40 more authors.
Nature Communications | Year: 2015

The incidence and death rate of pancreatic ductal adenocarcinoma (PDAC) have increased in recent years, therefore the identification of novel targets for treatment is extremely important. Interactions between cancer and stromal cells are critically involved in tumour formation and development of metastasis. Here we report that PDAC cells secrete BAG3, which binds and activates macrophages, inducing their activation and the secretion of PDAC supporting factors. We also identify IFITM-2 as a BAG3 receptor and show that it signals through PI3K and the p38 MAPK pathways. Finally, we show that the use of an anti-BAG3 antibody results in reduced tumour growth and prevents metastasis formation in three different mouse models. In conclusion, we identify a paracrine loop involved in PDAC growth and metastatic spreading, and show that an anti-BAG3 antibody has therapeutic potential. © 2015 Macmillan Publishers Limited. All rights reserved. Source

Discover hidden collaborations